No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Even After Rising 8.8% This Past Week, Hunan Er-Kang Pharmaceutical (SZSE:300267) Shareholders Are Still Down 44% Over the Past Five Years
Hunan Er-kang Pharmaceutical (300267.SZ): It is expected to incur a loss of 0.29 billion yuan to 0.39 billion yuan in 2024.
On January 21, Gronghui reported that Hunan Er-kang Pharmaceutical (300267.SZ) announced that it expects a loss of 290 million to 390 million yuan in 2024, with a non-recurring loss of 296.45 million to 396.45 million yuan. 1. During the reporting period, changes occurred in the market supply and demand relationship for the company's pharmaceutical intermediates, composite excipients, and other products, leading to a decrease in sales volume and a significant drop in sales prices, which affected the company's profitability; additionally, investment losses in associated companies were proportionately recognized. 2. Based on the principle of prudence, the company will recognize impairment for assets showing signs of impairment within the consolidated financial statements, following the relevant regulations.
Erkang Pharmaceuticals: 2024 Annual Results Forecast
Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) Top Holders Are Insiders and They Are Likely Disappointed by the Recent 11% Drop
Hunan Er-Kang Pharmaceutical (SZSE:300267 Shareholders Incur Further Losses as Stock Declines 6.6% This Week, Taking Five-year Losses to 55%
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
